Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen
PASADENA, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24arwr&src=ctag" target="_blank"gt;$arwrlt;/agt;–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has begun dosing in a new triple…